Clinical trials: Escherichia Coli Bacteremia
Infection Due to ESBL Escherichia Coli
Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli
Enterobacterieaceae (and specially Escherichia coli) showing resistance due to multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by chromosomal mechanisms have spread worldwide during the…
- Trial name
- FOREST (NCT02142751)
- Testing
- Fosfomycin sodium intravenous, Meropenem intravenous, Ceftriaxone intravenous
- Where
- 22 sites in Spain
- Volunteers
- 161 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Bacteremia Sepsis
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia
The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K.
- Trial name
- PHENOTECH-1 (NCT05613322)
- Testing
- Resistell Phenotech
- Where
- 3 sites in Austria, Spain and 1 more
- Volunteers
- 246 people
- Sponsor
- Resistell AG
Escherichia Coli Bacteremia, Klebsiella Bacteraemia
Switch to Oral Antibiotics in Gram-negative Bacteremia
Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have…
- Conditions
- Escherichia Coli Bacteremia, Klebsiella Bacteraemia, Enterobacter Bacteraemia, Serratia Bacteraemia
- Trial name
- SOAB (NCT04146922)
- Testing
- Step down to oral antimicrobial therapy, IV antimicrobial therapy
- Where
- 7 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 176 people
- Sponsor
- Hamad Medical Corporation
Bloodstream Infection, Sepsis
Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections
Background: Survival in Granzyme A gene (gzmA) knocked-out mice was significantly longer than in wild-type mice in a murine peritonitis model (cecal ligation puncture).
- Conditions
- Bloodstream Infection, Sepsis, Pathogenesis, Escherichia Coli Bacteremia
- Trial name
- GABEC (NCT03991793)
- Volunteers
- 50 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Urinary Tract Infections
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
The aim is to identify genomic determinants (genes or gene clusters) associated with the severity of community-acquired E. coli urinary tract infections in Guadeloupe through a comparative approach integrating clinical…
- Trial name
- COLIGENURI (NCT07905638)
- Testing
- Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)
- Volunteers
- 210 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Gram-negative Bacteremia
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of…
- Trial name
- GOAT (NCT06080698)
- Testing
- Intravenous Antibiotics, Oral Antibiotics
- Where
- 11 sites in United States
- Volunteers
- 1,030 people
- Sponsor
- Johns Hopkins University
Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor
The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421
In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes. E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. In Europe, bacteremia E.
- Trial name
- MoBaCo (NCT02847065)
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Nantes University Hospital
Community Acquired Infection
Community-Onset Bacteremia Due to ESBL Producing E.Coli or K.Pneumoniae in China: Prevalence, Risk Factors and Prognosis
Escherichia coli is the leading cause of community-onset gram-negative bloodstream infections. There has been a dramatic increase in the prevalence of extended-spectrum b-lactamases producing E.
- Trial name
- NCT01961206
- Testing
- bacteremia caused by ESBL producing E.coli or K.pneumoniae
- Where
- China
- Volunteers
- 960 people
- Sponsor
- Jian-cang Zhou M.D.